Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zejula
Marketing
AstraZeneca and Merck's Lynparza set to 'dominate' PARP market
AZ and Merck were the first to grab an FDA approval for Lynparza, and, despite growing competition, the drug is set to remain top in the PARP space.
Ben Adams
Apr 24, 2024 8:23am
AZ, GSK make case for broad I-O uses in endometrial cancer
Mar 18, 2024 11:05am
In royalty dispute, UK appeals court sides with GSK over AZ
Feb 14, 2024 8:22am
GSK tees up AstraZeneca rivalry with Jemperli-Zejula combo data
Dec 18, 2023 11:13am
FDA signs off on J&J's prostate cancer combo therapy Akeega
Aug 14, 2023 11:52am
'Eligibility challenges' derail GSK's Zejula breast cancer trial
Apr 26, 2023 1:57pm